📰 Celtic Atao News
Celtic Atao News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Celtic Atao. Real-time updates on events, politics, business and more.
September 26, 2022
First patient dosed with ATA-100 gene replacement therapy for LGMD-R9 On-going multicenter, Phase 1/2 study evaluating safety, pharmacodynamic and efficacy of ATA-100 Atamyo Therapeutics
February 24, 2022
Additional approval of Clinical Trial Application received from Denmark Danish Medicines Agency (DKMA) Orphan Drug Designation awarded from US FDA and European EMA Non-dilutive public
February 24, 2022
Additional approval of Clinical Trial Application received from Denmark Danish Medicines Agency (DKMA) Orphan Drug Designation awarded from US FDA and European EMA Non-dilutive public
October 26, 2021
Company also appoints Sophie Olivier, M.D., Chief Medical Officer, joining co-founders Stephane Degove, Chief Executive Officer, and Isabelle Richard, Ph.D., Chief Scientific Officer Atamyo is a